Eradication of Helicobacter pylori Infection Reduces the Incidence of Peptic Ulcer Disease in Patients using Nonsteroidal Anti-Inflammatory Drugs: A Meta-Analysis

Helicobacter

Volumn 17, Issue 4, 2012, Pages 286-296

  Tang, Chun Li ^a   Ye, Feng ^a   Liu, Wei ^a   Pan, Xiao Lin ^a   Qian, Juan ^a   Zhang, Guo Xin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Eradication; H. pylori; Meta analysis; NSAID; Peptic ulcer

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; ASIAN; DISEASE CONTROL; DRUG USE; EMBASE; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; INCIDENCE; MEDLINE; META ANALYSIS; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASIA; CLINICAL TRIALS AS TOPIC; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER; YOUNG ADULT;

HELICOBACTER PYLORI;

EID: 84863586190     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2012.00942.x     Document Type: Article

References (43)

1. Hunt RH, Bazzoli F. Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing Aliment Pharmacol Ther 2004;1:9-16.
2. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
3. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol 1997;24:2-17.
4. Chan FK, Sung JJ, Chung SC, To KF, Yung MY, Leung VK, Lee YT, Chan CS, Li EK, Woo J. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350:975-9.
5. Heresbach D, Raoul JL, Bretagne JF, Minet J, Donnio PY, Ramée MP, Siproudhis L, Gosselin M. Helicobacter pylori: a risk and severity factor of non-steroidal anti-inflammatory drug induced gastropathy. Gut 1992;33:1608-11.
6. Santucci L, Fiorucci S, Patoia L, Di Matteo FM, Brunori PM, Morelli A. Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens. Dig Dis Sci 1995;40:2074-80.
7. Graham DY, Lidsky MD, Cox AM, Evans DJ Jr, Evans DG, Alpert L, Klein PD, Sessoms SL, Michaletz PA, Saeed ZA. Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection. Gastroenterology 1991;100:1653-7.
8. Loeb DS, Talley NJ, Ahlquist DA, Carpenter HA, Zinsmeister AR. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role or Helicobacter pylori. Gastroenterology 1992;102:1899-905.
9. Santolaria S, Lanas A, Benito R, Pérez-Aisa M, Montoro M, Sainz R. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users. Aliment Pharmacol Ther 1999;13:1511-8.
10. Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994;89(Suppl 8):S116-28.
11. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
12. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, Shekelle P. A meta analysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol 2002;29:804-12.
13. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
14. Gabriel SE, Jaakkimainen L, Gombardier G. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-96.
15. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22.
16. Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A, Wason CM, Peacock RA, Gillon KR. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998;352:1016-21.
17. de Leest HTJI, Steen KSS, Lems WF, et al. Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID treatment: double-blind, randomized, placebo-controlled trial. Helicobacter 2007;12:477-85.
18. Venerito M, Malfertheiner P. Interaction of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in gastric and duodenal ulcers. Helicobacter 2010;15:239-50.
19. Murakami K, Okimoto T, Kodama M, et al. Helicobacter pylori and NSAID-induced gastric ulcer in a Japanese population. J Gastroenterol 2009;44(Suppl 19):40-3.
20. Nakayama M, Iwakiri R, Hara M, Ootani H, Shimoda R, Tsunada S, Sakata H, Fujimoto K. Low-dose aspirin is a prominent cause of bleeding ulcers in patients who underwent emergency endoscopy. J Gastroenterol 2009;44:912-8.
21. Shimizu S, Nakamura S, Kishino M, Konishi H, Shiratori K. Role of antithrombotic therapy and nonsteroidal anti-inflammatory drug use in bleeding gastroduodenal ulcers. Intern Med 2009;48:631-7.
22. Lee SW, Chang CS, Lee TY, Yeh HZ, Tung CF, Peng YC. Risk factors and therapeutic response in Chinese patients with peptic ulcer disease. World J Gastroenterol 2010;16:2017-22.
23. Nakashima S, Arai S, Mizuno Y, et al. A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2005;21(Suppl2):60-6.
24. Caselli M, Pazzi P, LaCorte R, Aleotti A, Trevisani L, Stabellini G. Campylobacter-like organisms, nonsteroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis. Digestion 1989;44:101-4.
25. Taha AS, Angerson W, Nakshabendi I, Beekman H, Morran C, Sturrock RD, Russell RI. Gastric and duodenal mucosal blood flow in patients receiving non-steroidal anti-inflammatory drugs--influence of age, smoking, ulceration and Helicobacter pylori. Aliment Pharmacol Ther 1993;7:41-5.
26. Kordecki H, Kurowski M, Kosik R, Pilecka D. Is Helicobacter pylori infection a risk or protective factor for mucosal lesions development in patients chronically treated with acetylsalicylic acid?. J Physiol Pharmacol 1997;48(Suppl 4):85-91.
27. Voutilainen M, Sokka T, Juhola M, Farkkilä M, Hannonen P. Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationships to gastric histology, Helicobacter pylori infection, and other risk factors for peptic ulcer. Scand J Gastroenterol 1998;33:811-6.
28. Matsukawa Y, Aoki M, Nishinarita S, et al. Prevalence of Helicobacter pylori in NSAID users with gastric ulcer. Rheumatology (Oxford) 2003;42:947-50.
29. Yajima H, Yamao J, Fukui H, Takakura Y. Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis. J Orthop Sci 2007;12:341-6.
30. Shiotani A, Sakakibara T, Yamanaka Y, Imamura H, Taruma K, Manabe N, Kamada T, Kusunoki H, Hata J, Haruma K. Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin. J Gastroenterol 2009;44:126-31.
31. Sokic-Milutinovic A, Krstic M, Rozer-Smolovic B, Alempijevic T. Role of Helicobacter pylori infection in gastroduodenal damage in patients starting NSAID therapy: 4months follow-up study. Dig Dis Sci 2010;55:2887-92.
32. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002;359:9-13.
33. Lai KC, Lau CS, Ip WY, Wong BC, Hui WM, Hu WH, Wong RW, Lam SK. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003;17:799-805.
34. Labenz J, Blum AL, Bolten WW, Dragosics B, Rösch W, Stolte M, Joelz HR. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002;51:329-35.
35. You JH, Lau W, Lee IY, Yung M, Ching JY, Chan FK, Lee KK. Helicobacter pylori eradication prior to initiation of long-term non-steroidal anti-inflammatory drug therapy in Chinese patients - a cost effectiveness analysis. Int J Clin Pharmacol Ther 2006;44:149-53.
36. Mizokami Y, Narushima K, Shiraishi T, Otsubo T, Narasaka T, Matsuoka T. Non-Helicobacter pylori ulcer disease in rheumatoid arthritis patients receiving long-term NSAID therapy. J Gastroenterol 2000;35(Suppl 12):38-41.
37. Ng TM, Fock KM, Khor JL, Teo EK, Sim CS, Tan AL, Machin D. Non-steroidal anti-inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer. Aliment Pharmacol Ther 2000;14:203-9.
38. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
39. Rich M, Scheiman JM. Nonsteroidal anti-inflammatory drug gastropathy at the new millennium: mechanisms and prevention. Semin Arthritis Rheum 2000;30:167-79.
40. Barkin J. The relation between Helicobacter pylori and nonsteroidal anti-inflammatory drugs. Am J Med 1998;105:22S-7S.
41. Chan FK, Sung JJ. How does Helicobacter pylori infection interact with non-steroidal anti-inflammatory drugs? Baillieres Best Pract Res Clin Gastroenterol 2000;14:161-72.
42. Fiorucci S, Antonelli E, Morelli O, Morelli A. Pathogenesis of non-steroidal anti-inflammatory drug gastropathy. Ital J Gastroenterol Hepatol 1999;31(Suppl 1):S6-13.
43. Bodger K, Wyatt JI, Heatley RV. Gastric mucosal secretion of interleukin-10: relations to histopathology, Helicobacter pylori status, and tumour necrosis factor-alpha secretion. Gut 1997;40:739-44.